Related Experiment Videos
Lymphocytic myocarditis and dilated cardiomyopathy: treatment with immunosuppressive agents
Insights
Immunosuppressive therapy for lymphocytic myocarditis showed mixed results. While it improved heart function in some patients, serious side effects were common, and survival was not linked to histologic improvement.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Lymphocytic myocarditis is a serious condition often leading to congestive heart failure and dilated cardiomyopathy.
- Standard therapy for congestive heart failure may not be sufficient for all patients with lymphocytic myocarditis.
Purpose of the Study:
- To evaluate the efficacy and safety of immunosuppressive agents (prednisone and azathioprine) in patients with lymphocytic myocarditis.
- To determine if histologic improvement correlates with clinical outcomes and survival.
Main Methods:
- Thirty-four patients with biopsy-proven lymphocytic myocarditis received immunosuppressive therapy for six months alongside standard heart failure treatment.
- Outcomes assessed included histologic findings, left ventricular ejection fraction, functional class, and survival rates.
Main Results:
- Seventy-three percent of patients showed improvement or resolution of lymphocytic infiltrates.
- Histologic improvement was unpredictable and did not correlate with baseline characteristics.
- Left ventricular ejection fraction improved significantly with treatment, but survival and functional class improvements were not consistently linked to histologic response.
- Serious or fatal side effects occurred in 24% of patients.
Conclusions:
- Immunosuppressive therapy can improve left ventricular ejection fraction in lymphocytic myocarditis but carries significant risks.
- Histologic improvement does not reliably predict clinical benefit or survival.
- Treatment decisions require careful consideration of individual patient risks and potential benefits.
Abstract:
Thirty-four patients with history of congestive heart failure, dilated cardiomyopathy, and biopsy-proven lymphocytic myocarditis were treated for six months with immunosuppressive agents (prednisone and azathioprine) in addition to standard therapy for congestive heart failure. Seventy-three percent had improvement or resolution of the lymphocytic infiltrate, whereas 27% had persistent infiltrates. Improvement in myocardial histologic findings was unpredictable and did not correlate with age, gender, duration of symptoms, initial functional class, severity of left ventricular dysfunction, intensity of initial inflammatory infiltrate, or degree of myocardial cell injury. Histologic response was associated with significant improvement in left ventricular ejection fraction, but not cardiothoracic ratio, left ventricular dimensions, or survival. Functional class improved equally whether patients' disease did or did not respond to the treatment, and was not necessarily associated with objective improvement in cardiac function. Immunosuppressive therapy resulted in serious or fatal side effects in 24% of patients. Overall long-term survival was 79% at one year and 76% at two years. Poor survival was related to left ventricular ejection fraction less than 20%, male sex, age less than 50 years, and marked left ventricular dilation, but not to myocardial histologic findings. These findings indicate that the potential benefits nu the risks of immunosuppressive therapy must be weighed carefully in the individual patient.